Cytokinetics Inc. (CYTK) — Analysis Summary
Cytokinetics Inc. (CYTK) has a market cap of $8.75B with year-over-year revenue growth of +376.6%. Net margin stands at -891.6%. The stock trades at a P/E ratio of -9.8.
Key Takeaways
- Revenue changed +376.6% year-over-year
- Net margin of -891.6%
- P/E ratio of -9.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, CYTK posted revenue growth of +376.6% and trades at a P/E of -9.8.
Cytokinetics Inc. (CYTK)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -1046.1% — severe operating losses
Net margin at -1321.1% — losses exceed revenue (possible one-time charges)
Revenue fell 23.1% vs the prior period.
Shareholder equity is negative, which can signal balance-sheet stress.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
673
Headquarters
SOUTH SAN FRANCISCO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.